KIT D816V‐Negative Smoldering Systemic Mastocytosis in an Adolescent Treated With Midostaurin
- 3 November 2026
- journal article
- Published by Wiley in Pediatric Blood & Cancer
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Reconsidering cytoreductive therapy in high-risk pediatric mastocytosis: From diffuse cutaneous to smoldering systemic diseaseJournal of Allergy and Clinical Immunology: Global, 2026
- Aggressive Systemic Mastocytosis Related to Germline p.D816V KIT MutationPediatric Blood & Cancer, 2025
- Neonatal Aggressive Systemic Mastocytosis Treated With Midostaurin and Systematic Review of the LiteraturePediatric Dermatology, 2025
- Characteristics and Therapeutic Strategies for Diffuse Cutaneous MastocytosisJAMA Dermatology, 2025
- Systemic Mastocytosis: Current Status and Challenges in 2024Blood Advances, 2025
- Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and managementAmerican Journal of Hematology, 2023
- Hematopoietic KIT D816Y mutation presenting as in utero aggressive systemic mastocytosis with response to midostaurinThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experienceAmerican Journal of Hematology, 2022
- Treatment of systemic mastocytosis in an infant with midostaurinThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Efficacy and Safety of Midostaurin in Advanced Systemic MastocytosisNew England Journal of Medicine, 2016